According to a report by Intel Market Research, the global Humira Market was valued at USD 13.12 billion in 2024 and is projected to decline from USD 12.08 billion in 2025 to USD 6.90 billion by 2032, registering a negative CAGR of -9.0% during the forecast period. The market is undergoing a significant transformation following the expiration of key patents and the rapid entry of biosimilar competitors, resulting in increased pricing pressure and substantial market share erosion for the originator product.

Humira (adalimumab), a tumor necrosis factor (TNF) inhibitor developed by AbbVie, has long been one of the world's best-selling biologic therapies. The drug is widely used for the treatment of chronic inflammatory and autoimmune conditions, including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, and plaque psoriasis. Its broad range of approved indications and extensive clinical history have established Humira as a cornerstone therapy across multiple medical specialties.

Download Sample Report: https://www.intelmarketresearch.com/humira-market-market-16317

The market's contraction is primarily driven by the loss of patent exclusivity in major markets, particularly the United States, where multiple biosimilar versions of adalimumab entered the market following patent expiration in 2023. Biosimilar manufacturers are offering lower-cost alternatives, encouraging healthcare providers, insurers, and pharmacy benefit managers to adopt more cost-effective treatment options. As a result, pricing competition has intensified, accelerating the decline in revenue generated by the branded Humira product.

Despite these challenges, demand for adalimumab-based therapies remains strong due to the growing prevalence of chronic inflammatory diseases worldwide. Rising diagnosis rates, expanding healthcare access, and increasing awareness of autoimmune disorders continue to support treatment adoption. Additionally, the availability of lower-cost biosimilars is improving patient access to biologic therapies, particularly in emerging markets where affordability has historically been a barrier.

Manufacturers are focusing on product differentiation strategies, including high-concentration citrate-free formulations, enhanced patient support programs, and improved self-administration devices to retain patient loyalty and maintain market presence. Furthermore, opportunities remain in emerging economies across Asia-Pacific, Latin America, and the Middle East, where expanding healthcare infrastructure and growing demand for advanced biologic treatments are expected to support future market growth.

North America remains the largest regional market due to its high biologic therapy adoption rates, established reimbursement systems, and large patient population. However, Europe continues to lead in biosimilar adoption, creating a highly competitive environment that serves as a model for future market developments worldwide.

Key Players Operating in the Humira Market:

• AbbVie Inc.
• Amgen Inc.
• Boehringer Ingelheim
• Sandoz International GmbH (Novartis)
• Coherus BioSciences, Inc.
• Fresenius Kabi
• Viatris Inc.
• Organon & Co.
• Pfizer Inc.
• Samsung Bioepis
• Cadila Healthcare Ltd. (Zydus Cadila)
• Torrent Pharmaceuticals Ltd.
• Eisai Co., Ltd.
• Celltrion Inc.

Download Sample Report: https://www.intelmarketresearch.com/humira-market-market-16317

Get Full Report: https://www.intelmarketresearch.com/humira-market-market-16317

As the global biologics landscape continues to evolve, market participants are expected to focus on competitive pricing strategies, biosimilar expansion, product innovation, and patient-centric solutions to navigate the changing dynamics of the Humira market and capitalize on emerging opportunities worldwide.

🌐 Website: https://www.intelmarketresearch.com

📞 Asia-Pacific: +91 9169164321 🔗

 LinkedIn: Follow Us